Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Transcatheter Versus Surgical Aortic Valve Replacement: Propensity-Matched Comparison.

Brennan JM, Thomas L, Cohen DJ, Shahian D, Wang A, Mack MJ, Holmes DR, Edwards FH, Frankel NZ, Baron SJ, Carroll J, Thourani V, Tuzcu EM, Arnold SV, Cohn R, Maser T, Schawe B, Strong S, Stickfort A, Patrick-Lake E, Graham FL, Dai D, Li F, Matsouaka RA, O'Brien S, Li F, Pencina MJ, Peterson ED.

J Am Coll Cardiol. 2017 Jul 25;70(4):439-450. doi: 10.1016/j.jacc.2017.05.060.

2.

Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.

Reed SD, Neilson MP, Gardner M, Li Y, Briggs AH, Polsky DE, Graham FL, Bowers MT, Paul SC, Granger BB, Schulman KA, Whellan DJ, Riegel B, Levy WC.

Am Heart J. 2015 Nov;170(5):951-60. doi: 10.1016/j.ahj.2015.08.015. Epub 2015 Aug 20.

3.

Reliability and construct validity of PROMIS® measures for patients with heart failure who undergo heart transplant.

Flynn KE, Dew MA, Lin L, Fawzy M, Graham FL, Hahn EA, Hays RD, Kormos RL, Liu H, McNulty M, Weinfurt KP.

Qual Life Res. 2015 Nov;24(11):2591-9. doi: 10.1007/s11136-015-1010-y. Epub 2015 Jun 3.

4.

HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice.

MacLeod SH, Elgadi MM, Bossi G, Sankar U, Pisio A, Agopsowicz K, Sharon D, Graham FL, Hitt MM.

Cancer Gene Ther. 2012 Dec;19(12):888-98. doi: 10.1038/cgt.2012.79. Epub 2012 Oct 26.

PMID:
23099884
5.

Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions.

Reed SD, Li Y, Kamble S, Polsky D, Graham FL, Bowers MT, Samsa GP, Paul S, Schulman KA, Whellan DJ, Riegel BJ.

Circ Cardiovasc Qual Outcomes. 2012 Jan;5(1):113-9. doi: 10.1161/CIRCOUTCOMES.111.962977. Epub 2011 Dec 6.

6.

Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice.

Gabaglia CR, DeLaney A, Gee J, Halder R, Graham FL, Gauldie J, Sercarz EE, Braciak TA.

J Transl Med. 2010 Oct 14;8:98. doi: 10.1186/1479-5876-8-98.

7.

Economic evaluation of home blood pressure monitoring with or without telephonic behavioral self-management in patients with hypertension.

Reed SD, Li Y, Oddone EZ, Neary AM, Orr MM, Grubber JM, Graham FL, Olsen MK, Svetkey LP, Dolor RJ, Powers BJ, Adams MB, Bosworth HB.

Am J Hypertens. 2010 Feb;23(2):142-8. doi: 10.1038/ajh.2009.215. Epub 2009 Nov 19.

8.

Outcomes of inpatients with and without sickle cell disease after high-volume surgical procedures.

Dinan MA, Chou CH, Hammill BG, Graham FL, Schulman KA, Telen MJ, Reed SD.

Am J Hematol. 2009 Nov;84(11):703-9. doi: 10.1002/ajh.21520. Erratum in: Am J Hematol. 2011 Oct;86(10):906-8.

9.

Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes.

De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ.

Am J Hematol. 2008 Jan;83(1):19-25.

10.
11.

Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.

See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, Rowe T, Zitzow LA, Karunakaran KP, Hitt MM, Graham FL, Prevec L, Mahony JB, Sharon C, Auperin TC, Rini JM, Tingle AJ, Scheifele DW, Skowronski DM, Patrick DM, Voss TG, Babiuk LA, Gauldie J, Roper RL, Brunham RC, Finlay BB.

J Gen Virol. 2006 Mar;87(Pt 3):641-50.

PMID:
16476986
13.

Analysis of ALDH1A2, CYP26A1, CYP26B1, CRABP1, and CRABP2 in human neural tube defects suggests a possible association with alleles in ALDH1A2.

Deak KL, Dickerson ME, Linney E, Enterline DS, George TM, Melvin EC, Graham FL, Siegel DG, Hammock P, Mehltretter L, Bassuk AG, Kessler JA, Gilbert JR, Speer MC; NTD Collaborative Group.

Birth Defects Res A Clin Mol Teratol. 2005 Nov;73(11):868-75.

PMID:
16237707
14.

Correction of chromosomal mutation and random integration in embryonic stem cells with helper-dependent adenoviral vectors.

Ohbayashi F, Balamotis MA, Kishimoto A, Aizawa E, Diaz A, Hasty P, Graham FL, Caskey CT, Mitani K.

Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13628-33. Epub 2005 Sep 7.

15.

Early adult-onset POAG linked to 15q11-13 using ordered subset analysis.

Allingham RR, Wiggs JL, Hauser ER, Larocque-Abramson KR, Santiago-Turla C, Broomer B, Del Bono EA, Graham FL, Haines JL, Pericak-Vance MA, Hauser MA.

Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2002-5.

16.

SNPs in the neural cell adhesion molecule 1 gene (NCAM1) may be associated with human neural tube defects.

Deak KL, Boyles AL, Etchevers HC, Melvin EC, Siegel DG, Graham FL, Slifer SH, Enterline DS, George TM, Vekemans M, McClay D, Bassuk AG, Kessler JA, Linney E, Gilbert JR, Speer MC.

Hum Genet. 2005 Jul;117(2-3):133-42. Epub 2005 May 10.

17.

Life-long systemic protection in mice vaccinated with L. major and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes.

Gabaglia CR, Sercarz EE, Diaz-De-Durana Y, Hitt M, Graham FL, Gauldie J, Braciak TA.

Vaccine. 2004 Nov 25;23(2):247-57.

PMID:
15531044
18.

Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice.

Maelandsmo GM, Ross PJ, Pavliv M, Meulenbroek RA, Evelegh C, Muruve DA, Graham FL, Parks RJ.

J Gene Med. 2005 Mar;7(3):307-15.

PMID:
15515146
19.

Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.

Rawle FE, Shi CX, Brown B, McKinven A, Tinlin S, Graham FL, Hough C, Lillicrap D.

J Gene Med. 2004 Dec;6(12):1358-68.

PMID:
15493040
21.

TERC is not a major gene in human neural tube defects.

Benz LP, Swift FE, Graham FL, Enterline DS, Melvin EC, Hammock P, Gilbert JR, Speer MC, Bassuk AG, Kessler JA, George TM; NTD Collaborative Group.

Birth Defects Res A Clin Mol Teratol. 2004 Aug;70(8):531-3.

PMID:
15329831
22.

Development of a size-restricted pIX-deleted helper virus for amplification of helper-dependent adenovirus vectors.

Sargent KL, Ng P, Evelegh C, Graham FL, Parks RJ.

Gene Ther. 2004 Mar;11(6):504-11.

PMID:
14999222
23.

Functional rescue of vitamin C synthesis deficiency in human cells using adenoviral-based expression of murine l-gulono-gamma-lactone oxidase.

Ha MN, Graham FL, D'Souza CK, Muller WJ, Igdoura SA, Schellhorn HE.

Genomics. 2004 Mar;83(3):482-92.

PMID:
14962674
24.

Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice.

Brown BD, Shi CX, Rawle FE, Tinlin S, McKinven A, Hough C, Graham FL, Lillicrap D.

J Thromb Haemost. 2004 Jan;2(1):111-8.

26.
27.

A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.

Trudel S, Trachtenberg J, Toi A, Sweet J, Li ZH, Jewett M, Tshilias J, Zhuang LH, Hitt M, Wan Y, Gauldie J, Graham FL, Dancey J, Stewart AK.

Cancer Gene Ther. 2003 Oct;10(10):755-63.

PMID:
14502228
28.

Lack of association of mutations in optineurin with disease in patients with adult-onset primary open-angle glaucoma.

Wiggs JL, Auguste J, Allingham RR, Flor JD, Pericak-Vance MA, Rogers K, LaRocque KR, Graham FL, Broomer B, Del Bono E, Haines JL, Hauser M.

Arch Ophthalmol. 2003 Aug;121(8):1181-3.

29.

Protection against experimental autoimmune encephalomyelitis generated by a recombinant adenovirus vector expressing the V beta 8.2 TCR is disrupted by coadministration with vectors expressing either IL-4 or -10.

Braciak TA, Pedersen B, Chin J, Hsiao C, Ward ES, Maricic I, Jahng A, Graham FL, Gauldie J, Sercarz EE, Kumar V.

J Immunol. 2003 Jan 15;170(2):765-74.

30.

Reduction in the minimum candidate interval in the dominant-intermediate form of Charcot-Marie-Tooth neuropathy to D19S586 to D19S432.

Speer MC, Graham FL, Bonner E, Collier K, Stajich JM, Gaskell PC, Pericak-Vance MA, Vance JM.

Neurogenetics. 2002 Oct;4(2):83-5.

PMID:
12481986
31.

A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10).

Reid E, Kloos M, Ashley-Koch A, Hughes L, Bevan S, Svenson IK, Graham FL, Gaskell PC, Dearlove A, Pericak-Vance MA, Rubinsztein DC, Marchuk DA.

Am J Hum Genet. 2002 Nov;71(5):1189-94. Epub 2002 Sep 24.

32.

Adenoviral-mediated gene transfer of lymphotactin to the lungs of mice and rats results in infiltration and direct accumulation of CD4+, CD8+, and NK cells.

Emtage PC, Xing Z, Wan Y, Zlotnik A, Graham FL, Gauldie J.

J Interferon Cytokine Res. 2002 May;22(5):573-82.

PMID:
12060496
33.

ErbB2 is required for muscle spindle and myoblast cell survival.

Andrechek ER, Hardy WR, Girgis-Gabardo AA, Perry RL, Butler R, Graham FL, Kahn RC, Rudnicki MA, Muller WJ.

Mol Cell Biol. 2002 Jul;22(13):4714-22.

34.

Construction of first-generation adenoviral vectors.

Ng P, Graham FL.

Methods Mol Med. 2002;69:389-414. No abstract available.

PMID:
11987791
35.

Preparation of helper-dependent adenoviral vectors.

Ng P, Parks RJ, Graham FL.

Methods Mol Med. 2002;69:371-88. No abstract available.

PMID:
11987790
36.

Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells.

Shaw G, Morse S, Ararat M, Graham FL.

FASEB J. 2002 Jun;16(8):869-71. Epub 2002 Apr 10.

PMID:
11967234
37.
39.

Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma.

Wen XY, Mandelbaum S, Li ZH, Hitt M, Graham FL, Hawley TS, Hawley RG, Stewart AK.

Cancer Gene Ther. 2001 May;8(5):361-70.

40.

Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma--a phase 1 study.

Trudel S, Li Z, Dodgson C, Nanji S, Wan Y, Voralia M, Hitt M, Gauldie J, Graham FL, Stewart AK.

Leukemia. 2001 May;15(5):846-54.

PMID:
11368448
41.

Development of a FLP/frt system for generating helper-dependent adenoviral vectors.

Ng P, Beauchamp C, Evelegh C, Parks R, Graham FL.

Mol Ther. 2001 May;3(5 Pt 1):809-15.

42.

Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes.

Pützer BM, Stiewe T, Rödicker F, Schildgen O, Rühm S, Dirsch O, Fiedler M, Damen U, Tennant B, Scherer C, Graham FL, Roggendorf M.

J Natl Cancer Inst. 2001 Mar 21;93(6):472-9.

PMID:
11259473
43.

Recombinant adenovirus vectors expressing interleukin-5 and -6 specifically enhance mucosal immunoglobulin A responses in the lung.

Braciak TA, Gallichan WS, Graham FL, Richards CD, Ramsay AJ, Rosenthal KL, Gauldie J.

Immunology. 2000 Nov;101(3):388-96.

44.

Adenovirus vectors for human gene therapy.

Hitt MM, Graham FL.

Adv Virus Res. 2000;55:479-505. Review. No abstract available.

PMID:
11050953
45.

Yeast recombinase FLP functions effectively in human cells for construction of adenovirus vectors.

Ng P, Cummings DT, Evelegh CM, Graham FL.

Biotechniques. 2000 Sep;29(3):524-6, 528.

46.

Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector.

O'Neal WK, Zhou H, Morral N, Langston C, Parks RJ, Graham FL, Kochanek S, Beaudet AL.

Mol Med. 2000 Mar;6(3):179-95.

47.

Adenovirus vectors for high-efficiency gene transfer into mammalian cells.

Graham FL.

Immunol Today. 2000 Sep;21(9):426-8. No abstract available.

PMID:
10953094
48.

Helper-dependent adenovirus vectors: their use as a gene delivery system to neurons.

Cregan SP, MacLaurin J, Gendron TF, Callaghan SM, Park DS, Parks RJ, Graham FL, Morley P, Slack RS.

Gene Ther. 2000 Jul;7(14):1200-9.

49.

Genome-wide scan for adult onset primary open angle glaucoma.

Wiggs JL, Allingham RR, Hossain A, Kern J, Auguste J, DelBono EA, Broomer B, Graham FL, Hauser M, Pericak-Vance M, Haines JL.

Hum Mol Genet. 2000 Apr 12;9(7):1109-17.

PMID:
10767336
50.

An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method.

Ng P, Parks RJ, Cummings DT, Evelegh CM, Graham FL.

Hum Gene Ther. 2000 Mar 20;11(5):693-9.

PMID:
10757349

Supplemental Content

Loading ...
Support Center